Loading
A phase 1/2 trial of RC118-ADC in advanced solid tumours, run by RemeGen Co., Ltd., now recruiting.
A Study of RC118 in Patients with Locally Advanced Unresectable or Metastatic Malignant Solid Tumors is a phase 1/2 interventional study registered as NCT05205850 by RemeGen Co., Ltd., with 135 participants planned, started 2022-03-03 and due to reach its primary completion in 2025-09-30. Interventions recorded: RC118-ADC.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares RC118-ADC, RemeGen, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares RemeGen, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares RemeGen, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares RemeGen and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/